# The Swedish National study on Aging and Care in Kungsholmen

https://neurodegenerationresearch.eu/survey/the-swedish-national-study-on-aging-and-care-in-kungsholmen/

**Title of the cohort**

The Swedish National study on Aging and Care in Kungsholmen

**Acronym for cohort**

SNAC-K

**Name of Principal Investigator**

| | |
|---|---|
| Title | Professor |
| First name | Laura |
| Last name | Fratiglioni |

**Address of institution where award is held**

| | |
|---|---|
| Institution | Aging Reseach Center |
| Street Address | |
| City | Stockholm |
| Postcode | 113 30 |

**Country**

- Sweden

**Website**

www.ki-su-arc.se

**Contact email**

laura.fratiglioni@ki.se

**Funding source**

**1. The cohort includes, or expects to include, incidence of the following conditions**

- Alzheimer’s disease and other dementias
- Parkinson’s disease

**When studies on the above condition(s) are expected to become possible**

- Already possible

**2a. Stated aim of the cohort**

To trace the changes in health status and detect factors leading to negative health and functional outcomes in the elderly

**2b. Features distinguishing this cohort from other population cohorts**
**3a. i) Number of publications that involve use of cohort to date**

4

**3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**
**3c. Information (i.e. research findings) expected to be gained from the population cohort**
**4a. Study criteria: age range of participants at recruitment**

Age in years from: 60 +

To ('until death' if applicable): until death

**4b. Study criteria: inclusion criteria**

60 + living in Kungsholmen area at 2001

**4c. Study criteria: exclusion criteria**

No

**5. Size of the cohort (i.e. number of participants enrolled)**

- 1,000 – 5,000 participants

**6a. Measures used to characterise participants**

As well as biological and genetic date

**6b. Additional measures for participants with a clinical disorder**

Yes

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

Dementia, Alzeimer, Parkinson and other cronical disorders

**7. Study design**

- Longitudinal

**8. Cases matched by**

- Other health assessment (specify) / N/A
- Not relevant

**9a. Does the study include a specialised subset of control participants**

- No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

01-01-2001

**10a. ii) Data collection end date**
**10a iii) Data collection for this study is**

- Data collection ongoing
- Data analysis ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

- Yes – funding applied for

**11. Data collected**

- Only through the study
- Through links to medical records

**12. System in place to enable re-contact with patients for future studies**

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

| | Yes/No | % available |
|---|---|---|
| Data summarised in database | yes | 100 |
| Database is web-based | | |
| Database on spreadsheet | yes | 100 |
| Database is on paper | yes | 100 |
| Other (specify) | | |

**Language used:**

Swedish

**13b. Format and availability of data held as individual records**

| | Yes/No | % available |
|---|---|---|
| Data held as individual records | | |
| Data is web-based | | |
| Data held on computer based records | yes | 100 |
| Data held on cards | | |
| Other (specify) | | |

**Language used:**

Swedish

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Resource has own ethics approval so usually no need for separate external ethics approval

**15. Data sharing policy specified as a condition of use**

- No policy exists

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors:blood
- Living donors: blood derivatives
- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Primary samples: Supplied fresh

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

**17. Is information on biological characteristics available to other groups**

- No
- Yes, for all the cohort